Louise Frederika Kooij Sells 43,872 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 43,872 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60. Following the transaction, the chief accounting officer directly owned 15,000 shares in the company, valued at $529,500. This represents a 74.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total transaction of $928,072.48.

NewAmsterdam Pharma Stock Down 0.8%

NASDAQ:NAMS opened at $34.74 on Wednesday. The firm’s fifty day simple moving average is $37.00 and its 200-day simple moving average is $29.23. The stock has a market cap of $3.94 billion, a PE ratio of -16.95 and a beta of 0.05. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $4.54 million. Equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAMS. Mather Group LLC. acquired a new position in NewAmsterdam Pharma in the 3rd quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of NewAmsterdam Pharma during the third quarter worth about $30,000. Quarry LP acquired a new position in shares of NewAmsterdam Pharma in the first quarter valued at approximately $25,000. Wolverine Asset Management LLC purchased a new position in shares of NewAmsterdam Pharma during the third quarter valued at approximately $69,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock worth $79,000 after acquiring an additional 662 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the subject of several research analyst reports. Royal Bank Of Canada raised their price objective on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. HC Wainwright began coverage on NewAmsterdam Pharma in a research report on Monday, October 20th. They issued a “buy” rating and a $52.00 price target for the company. Needham & Company LLC boosted their price objective on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Citigroup increased their price objective on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.90.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.